SAN FRANCISCO--Eos Biotechnology, a startup genomics company here, has announced a research collaboration with the Peter MacCallum Cancer Institute in Melbourne, Australia, to identify genes with diagnostic, prognostic, and therapeutic potential for breast and colorectal cancers.
One aim of the collaboration is to identify gene products associated with breast carcinogenesis and metastases by using gene expression profiling, deploying Affymetrix GeneChip arrays and Eos's DNA array technologies to assay expression of thousands of genes in parallel in clinical tissue collections derived from human breast carcinomas of known clinical stage and patient outcome.
The collaboration also aims to apply Eos's extensive database and knowledge of gene expression in colorectal cancers to the institute's colorectal cancer microarray panels, Eos announced. Gene targets will be further developed for early detection and staging of colorectal cancers, as well as for small-molecule drug targets.
Additionally, Eos announced the appointment of Gayle Mills to the position of vice-
president, business development. Mills previously served as vice-president, strategic marketing and business development, for the neurobiology business unit of Roche Bioscience. She also held a senior-level business development position with Affymax.